Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q1 FY20 results · Apr–Jun 2019
Marksans Pharma reported revenue from operations of ₹245.03 crore (up 4.2% from Q1 FY19) and net profit of ₹22.48 crore (down 9.6% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 245.03 | 235.25 | +4.2% | 247.41 | −1.0% |
| Other income | 2.18 | 3.23 | −32.7% | 9.73 | −77.6% |
| Total income | 247.21 | 238.49 | +3.7% | 257.14 | −3.9% |
| Profit before tax | 27.61 | 30.36 | −9.0% | 16.68 | +65.6% |
| Net profit for the period | 22.48 | 24.88 | −9.6% | 9.85 | +128.2% |
| Attributable to shareholders of the company | 21.31 | — | — | 8.51 | +150.4% |
| EPS, basic (₹) | 0.52 | 0.58 | −10.3% | 0.21 | +147.6% |
| Net margin (%) | 9.2 | 10.6 | 4.0 |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 92.42 | 93.14 | −0.8% | 91.18 | +1.4% |
| Other income | 2.15 | 3.22 | −33.3% | 9.50 | −77.4% |
| Total income | 94.57 | 96.36 | −1.9% | 100.69 | −6.1% |
| Profit before tax | 7.91 | 16.68 | −52.6% | 8.82 | −10.3% |
| Net profit for the period | 5.66 | 13.87 | −59.2% | 5.62 | +0.6% |
| EPS, basic (₹) | 0.14 | 0.34 | −58.8% | 0.14 | +0.0% |
| Net margin (%) | 6.1 | 14.9 | 6.2 |
Consolidated
- Filed with BSE
- 12 Aug 2019, 16:39 IST
- Board meeting
- 09 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Aug 2019, 16:39 IST
- Board meeting
- 09 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE